Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cell and gene therapy

- PMLiVE

UniQure gets speedy US review for Huntington’s gene therapy

Pioneer gaining momentum again

- PMLiVE

Roivant forms Asian cell therapy ‘vant’, with Medigene’s help

Latest venture taps into Asian talent and markets

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

- PMLiVE

Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

Will develop in silico models and novel algorithms

- PMLiVE

CHMP backs Lynparza in breast cancer, Dupixent in asthma

Akcea's FDA-rejected Waylivra also recommended

Gene Genie

Evolution will find new markets for gene and cell therapies

- PMLiVE

Roche buys gene therapy specialist Spark for $4.3bn

Can compete with rival Novartis in fast-developing area

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

- PMLiVE

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Former Horizon chief Darrin Disley to lead the company through series A round

Cell and gene therapy

Tackling the manufacturing cost and complexity challenges

EU flag

Europe’s medicines tracking system goes live

Covers 140,000 pharmacies in 28 countries

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links